Reach Us +44-1904-929220
Circulating DNA-Important Biomarker of Cancer | OMICS International | Abstract

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Circulating DNA-Important Biomarker of Cancer

Dachuan Jin1*, Suqing Xie2, Zhicheng Mo3, Yingjian Liang4 Baoqiang Guo5, Gengming Huang6 and Jianli Dong6

1University of Texas Health Science Center at San Antonio, Texas

2New York Medical College at Valhalla, USA

3Conemaugh Memorial Medical Center, USA

4St.Elizabeth’s Medical Center, Boston, MA, USA

5School of Medicine, The University of Manchester, UK

6University of Texas Medical Branch at Galveston

*Corresponding Author:
Dachuan Jin
Research Institute, The Methodist Hospital, Texas, USA
Tel: (832) 564-9081
E-mail: [email protected]

Received date: April 19, 2012; Accepted date: May 02, 2012; Published date: May 07, 2012

Citation: Jin D, Xie S, Mo Z, Liang Y, Guo B, et al. (2012) Circulating DNA-Important Biomarker of Cancer. J Mol Biomarkers Diagn S2:009. doi:10.4172/2155-9929.S2-009

Copyright: © 2012 Jin D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Circulating extracellular nucleic acids, especially DNA, was discovered more than sixty years ago, but it is becoming hot just in the last two decades because it is now widely recognized as a very promising biomarker for the early diagnosis, monitoring, and evaluation of prognosis of cancer. In addition, compared with traditional surgical approaches and other biochemical tests, circulating DNA as a biomarker, owns many obvious advantages. It is easily accessible, reliable, reproducible and early detectable in cancer. It is also very sensitive and specific if cancer specific DNA alterations are tested instead of elevation of circulating DNA concentration. But the clinical application of this biomarker is still just limited to obstetrics and prenatal diagnosis. This review throws light on its history, current research update and potential clinical application in cancer diagnosis and management. In addition, major detection technologies of circulating DNA are summarized concisely and comprehensively.

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page